Published in Medical Letter on the CDC and FDA, July 5th, 2009
"The REFORM trial completed enrollment in record time considering the small number of select investigative sites invited to participate in the trial," said Robert Bersin, M.D., the trial's principal investigator and medical director of endovascular services at Seattle Cardiology and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA